Alkeus Pharmaceuticals, Inc. is a later-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness, The firm's lead compound, ALK-001, is an oral investigational drug being developed for treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease
